NEW YORK (AP) — Shares of Vanda Pharmaceuticals Inc. climbed Tuesday after the company said the Food and Drug Administration is planning a faster review of its sleep disorder drug tasimelteon. That could bring the drug to market more quickly.

THE SPARK: Vanda said the FDA plans to complete its review by Jan. 31, taking less than the usual 10 months. It said a panel of FDA advisors will discuss the drug at a meeting on Nov. 14. A positive recommendation would improve the chances the drug will be approved.

Tasimelteon is intended to treat non-24-hour disorder, a rare disorder that affects blind people. Patients have difficulty lining up their sleep patterns with the 24 hours in a day because they can't detect light. Vanda said there are no approved treatments for the condition. The drug met its goals in one late-stage trial in December and in a second study in January.

THE BIG PICTURE: Vanda's only approved drug is the schizophrenia treatment Fanapt.

The company is scheduled to report its second-quarter results before the market opens on Wednesday.

THE ANALYSIS: Jefferies & Co. analyst Oren Livnat said the FDA's decision suggests that is sees non-24-hour disorder as an important unmet medical need and doesn't consider tasimelteon a typical insomnia drug. He maintained a "Buy" rating on Vanda shares and raised his price target to $13 from $11.

SHARE ACTION: The company's shares jumped 40 percent to $11.27 in morning trading. The stock has traded between $2.92 and $13.30 in the last 12 months.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel